Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.65 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL116218 | 0.99 | TRPV1 (0.64) | TRPV1ROCK2ROCK1MEN1MAPK1 | |
| SCHEMBL116573 | 0.86 | TRPV1 (0.63) | TRPV1MEN1MAPK1HTTBLM | |
| SCHEMBL117772 | 0.81 | TRPV1 (0.70) | TRPV1MEN1MAPK1HTTBLM | |
| SCHEMBL21127838 | 0.80 | TRPV1 (0.81) | TRPV1ROCK2ROCK1 | |
| SCHEMBL116716 | 0.79 | TRPV1 (0.55) | TRPV1 | |
| SCHEMBL4026073 | 0.79 | TRPV1 (1.00) | TRPV1MEN1MAPK1HTTBLM | |
| SCHEMBL15478234 | 0.79 | TRPV1 (0.65) | TRPV1MEN1MAPK1HTTBLM | |
| SCHEMBL30544195 | 0.78 | KDM4E (0.67) | TRPV1ROCK1MEN1MAPK1HTT | |
| SCHEMBL2315592 | 0.78 | KDM4E (0.67) | TRPV1ROCK1MEN1MAPK1HTT | |
| SCHEMBL5660097 | 0.77 | TRPV1 (0.71) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| WO-2010127330-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHAMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127329-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | SLC6A2, ROCK2, SLC6A4 | TRPV1 3131/4885ROCK2 2/4885ROCK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.